A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine- tositumomab

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6624-6632

  Press, Oliver W ^a   Unger, Joseph M ^a   Rimsza, Lisa M ^b   Friedberg, Jonathan W ^d   Leblanc, Michael ^a   Czuczman, Myron S ^e,f   Kaminski, Mark ^g   Braziel, Rita M ^h   Spier, Catherine ^b   Gopal, Ajay K ^a   Maloney, David G ^a   Cheson, Bruce D ^f,i   Dakhil, Shaker R ^j   Miller, Thomas P ^c   Fisher, Richard I ^k  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f Cancer and Leukemia Group B   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^j WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^k TEMPLE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER PROGNOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; EXPLORATORY RESEARCH; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SIZE; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; VINCRISTINE; YOUNG ADULT;

EID: 84890284204     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1120     Document Type: Article

References (38)

1. Press OW. Follicular lymphoma. In:Kaushansky K, Lichtman M, Beutler E, Kipps T, Seligsohn U, Prchal J, editors. Williams' hematology. 8th ed. New York, NY: McGraw-Hill; 2010. p. 1565-74.
2. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, et al. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2011;9:484-560.
3. Fisher RI, Le Blanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
4. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
5. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol 2006;24:1582-9.
6. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
7. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86.
8. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
9. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-6.
10. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Le Blanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:1606-12.
11. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9.
12. Press OW, Unger JM, Rimsza LM, Friedberg JW, Le Blanc M, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131) iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013;31:314-20.
13. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
14. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-62.
15. Harris NL, Swerdlow SH, Jaffe ES, Ott BN, Nathwani B, De Jong D, et al. Follicular Lymphoma. In:Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008. p. 220-6.
16. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lo Buglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:2454-60.
18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
19. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc Serv B 1972;34:187-220.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Rimsza LM, Unger JM, Tome ME, Leblanc ML. A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma. PloS ONE 2011;6:e22267.
22. Federico M, Luminari S, Dondi A, Sacchi S, Franco V, Pileri S, et al. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). J Clin Oncol 2012;30 (suppl; abstr 8006).
23. Rummel M, Niederle N, Maschmeyer G, Banat AG, Von Gruenhagen U, Losem C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 2012;30 (suppl; abstr 3).
24. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64.
25. Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-Line Indolent trial. J Clin Oncol 2013;31:1977-83.
26. Amlot PL, Adinolfi M. Serum beta 2 microglobulin and its prognostic value in lymphomas. Eur J Cancer 1979;15:791-6.
27. Canovas A, Alonso JJ, Barreiro G, Aguirre C. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin. Tumori 2010;96:117-21.
28. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991;114:855-60.
29. Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003;21:1996-2003.
30. Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 1990;75:823-30.
31. Bataille R, Klein B. Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acutephase proteins? Blood 1991;77:1616-7.
32. Neumann F, Gattermann N, Barthelmes HU, Haas R, Germing U. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. Leuk Res 2009;33:232-6.
33. Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, et al. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med 1992;93:599-604.
34. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 2002;95:2534-8.
35. Johnson PW, Whelan J, Longhurst S, Stepniewska K, Matthews J, Amess J, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993;67:792-7.
36. Scholz CW, Pinto A, Linkesch W, Linden O, Viardot A, Keller U, et al. (90) Yttrium-Ibritumomab-Tiuxetan as first-line treatment for follicular lymphoma: 30 months follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013;31:308-13.
37. Swan F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7:1518-27.
38. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.